Nuclear Medicine Radioisotopes Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Nuclear Medicine Radioisotopes Market Trends and Insights

Rising Prevalence of Cancer Requiring Theragnostic Isotopes

Cancer incidence is projected to reach 35 million new cases annually by 2050, up 77% from 2022, sustaining robust demand for theragnostic pairings that combine Gallium-68 imaging and Lutetium-177 therapy. Pluvicto, a Lutetium-177 agent, generated USD 1.4 billion sales in 2024, underscoring clinical uptake in metastatic prostate disease ^{[2]Novartis, “Pluvicto Performance,” novartis.com}. Regulatory agencies have shortened review times for radiopharmaceuticals, trimming European approval pathways by 18 months and helping expand access. Alpha emitters such as Actinium-225 enter late-stage trials for neuroendocrine tumors and acute myeloid leukemia, positioning the modality for the next growth wave. Supply chain bottlenecks for enriched targets remain, but investment in thorium-229 decay chains and high-energy cyclotrons signals future relief.

Growing Adoption of SPECT & PET Imaging in Cardiology

Updated reimbursement codes issued in 2024 opened PET stress testing to an additional 2.3 million U.S. patients per year ^{[3]American College of Cardiology, “PET Myocardial Perfusion Codes,” acc.org}. Rubidium-82 generator shipments climbed 34% year over year in Q3 2025, reflecting wider installation of dedicated cardiac PET-CT suites. Fluorine-18 flurpiridaz, boasting a 110-minute half-life, awaits FDA review and could enable centralized manufacture with regional shipping, lowering dose cost for rural hospitals. AI-based software that autoflags coronary plaque and scores calcium augments clinical value, furthering adoption momentum. The combined effect is faster scan throughput, improved diagnostic confidence, and incremental isotope consumption.

Expansion of Cyclotron Networks in Emerging Economies

China added 47 medical cyclotrons across 2024-2025, raising penetration to one unit per 4.5 million residents and cutting dependence on imported Fluorine-18. India earmarked USD 180 million for 12 regional cyclotron hubs, targeting cities with over 1 million population. Compact 9.6 MeV cyclotrons, commercialized in 2024, shrink footprint and slice capital cost by 40%, letting mid-size hospitals produce short-lived isotopes onsite. Distributed networks mitigate dose wastage tied to transport delays and widen access to Carbon-11 or Nitrogen-13 scans. As installation spreads, the nuclear medicine radioisotopes market gains a resilient regional supply.

U.S. Inflation Reduction Act Production-Tax Credits for Domestic Mo-99

Section 45X provides a USD 30 per Curie credit for U.S.-made Molybdenum-99, narrowing cost gaps with imported generators priced USD 1,200-1,500 each. NorthStar began commercial output in Wisconsin during 2025 using neutron-capture technology on non-uranium targets, instantly qualifying for the incentive. SHINE’s subcritical-assembly plant, slated for 2027, targets weekly capacity equal to one-third of national demand. The credit lowers breakeven by 22%, catalyzing private investment and cutting outage risk linked to foreign reactors.

Short Half-Life, Just-in-Time Logistics & Waste Challenges

Technetium-99m’s 6-hour half-life and Fluorine-18’s 110-minute half-life force round-the-clock pharmacy schedules and tight courier windows. A 2-hour transit delay trims Fluorine-18 activity 19%, wasting USD 800-1,200 doses and pushing scan reschedules. Rural sites more than 150 kilometers from a supplier cancel 14% more PET appointments, eroding patient access. Spent Mo-99 generators must decay ten half-lives before disposal, tying up shielded space and adding USD 50-80 handling cost per unit. Divergent waste rules between the United States and the European Union inflate compliance overhead and cloud cross-border service planning, restraining nuclear medicine radioisotopes market efficiency.

Aging Research-Reactor Fleet Limiting Isotope Output

The global research-reactor fleet averages 52 years old, and 18 of the 25 isotope-producing units face decommissioning or multi-year refurbishment over the next decade. OPAL in Australia, supplying 20% of Asia-Pacific Mo-99, endured a 9-month shutdown in 2024, forcing dose rationing across Southeast Asia. Oak Ridge’s High Flux Isotope Reactor, the lone U.S. Actinium-225 source, yields only 600 millicuries annually, far below therapeutic demand. Replacement reactors cost more than USD 500 million and require at least eight years to build, dissuading investors. Accelerator-based alternatives are promising but have yet to reach commercial scale, keeping supply vulnerability top of mind for the nuclear medicine radioisotopes industry.

Segment Analysis

By Type: Therapeutic Isotopes Gain Momentum

Diagnostic isotopes held 85.56% share in 2025, anchored by Technetium-99m bone, renal, and cardiac scans, alongside Fluorine-18 oncology imaging. Therapeutic isotopes, however, are projected to grow at an 11.45% CAGR and will narrow the gap as clinicians embrace targeted radionuclide therapy for metastatic prostate and neuroendocrine disease. Lutetium-177 alone generated signifcant share of radiopharmaceutical sales in 2025, highlighting buyer confidence in the modality. The nuclear medicine radioisotopes market size for the therapeutic segment is poised to widen as approval pipelines fill and reimbursement aligns with clinical evidence. 

Radioembolization with Yttrium-90 remains a niche but struggles to gain share against immune-oncology drugs. Iodine-131 volumes plateau where differentiated thyroid cancer incidence stabilizes. Radium-223 holds a beachhead in bone-metastatic prostate disease, while Actinium-225’s clinical pipeline, though supply-constrained, suggests multiyear growth potential. Gallium-68, produced from Germanium-68 generators but operationally akin to cyclotron workflows, displaced Fluorine-18 in prostate-specific membrane antigen scans as generator shipments rose notably in 2025. Together, these dynamics reshape value pools within the nuclear medicine radioisotopes market.

By Application: Oncology Overtakes Cardiology

Cardiology commanded 32.45% revenue in 2025 thanks to entrenched SPECT and emerging PET perfusion imaging. Yet oncology is forecast to post a 12.34% CAGR through 2031, surpassing heart-related use as theranostic pairings prove clinical and economic merit. The nuclear medicine radioisotopes market size for oncology procedures is expected to swell as FDA approvals, such as Pylarify, expand eligible patient cohorts. 

Neurology applications form a notable share in 2025, anchored by amyloid PET and dopamine transporter scans. Thyroid imaging and therapy maintain steady volumes around USD 380 million annually. Emerging tracers Copper-64, Zirconium-89, Terbium-161 remain below USD 15 million each but illustrate research diversity. Clinical-trial adoption creates early revenue that seeds future commercial launches, reinforcing the growth arc for the broader nuclear medicine radioisotopes market.

By Source: Cyclotron Routes Challenge Reactor Dominance

Reactor-derived isotopes still accounted for 82.11% share in 2025, aided by the ubiquity of Mo-99/Technetium-99m generators. Yet cyclotron-produced volumes are forecast to expand at an 11.78% CAGR as China, India, and Latin America deploy distributed production. The nuclear medicine radioisotopes market share for cyclotron routes will climb as travel-time losses fall and site-of-care manufacturing spreads. 

Fluorine-18 fluorodeoxyglucose remains the workhorse, with more than 4.2 million weekly doses in 2025. NorthStar’s neutron-capture Mo-99 process reached commercial scale and showed that alternative pathways can compete on cost. Power-reactor co-production demonstrated feasibility at Bruce Power, offering marginal-cost isotope streams. While photon-based production stays experimental, generator-produced Gallium-68 illustrates how hybrid supply models enrich the nuclear medicine radioisotopes market.

Note: Segment shares of all individual segments available upon report purchase

By End User: Pharma & Biotech Emerge as Growth Engine

Hospitals owned 59.33% share in 2025, reflecting their dominance as primary procedure sites with in-house radiopharmacies and imaging systems. Yet pharma and biotech companies are primed for a 12.44% CAGR as they scale contract manufacturing, broaden clinical trials, and integrate radionuclides into antibody-drug conjugates. The nuclear medicine radioisotopes market size tied to commercial-supply contracts is likely to grow quickly as advanced therapeutics enter late-stage trials.

Diagnostic imaging centers account for a significant revenue share, concentrated in metropolitan corridors. Academic institutes hold a notable share and focus on preclinical research and investigator-initiated trials. Outsourcing of Lutetium-177 synthesis for large multicenter studies exemplifies how service contracts migrate away from hospitals toward specialized GMP facilities, redefining demand flows in the nuclear medicine radioisotopes industry.

Geography Analysis

North America retained 43.3% share in 2025 thanks to dense PET infrastructure, Medicare coverage for 18 nuclear medicine procedures, and 187 cyclotrons that underpin short-lived isotope supply. The region remains the single largest buyer group, but growth moderates toward mature levels. 

Europe contributed significantly revenue, with centralized radiopharmacy models servicing multihospital networks via overnight courier. The European Union’s Critical Medicines Act earmarked EUR 240 million in subsidies for Mo-99 and Lutetium-177 production, supporting capacity additions in France, Germany, and the Netherlands.

Asia-Pacific is forecast to log a 12.02% CAGR to 2031, lifting its slice of the nuclear medicine radioisotopes market as China, India, Japan, and South Korea commission cyclotrons and localize Gallium-68 and Fluorine-18 manufacture. Middle East & Africa, at a notable share, relies on South Africa’s Safari-1 reactor, but outages curb growth. South America, led by Brazil and Argentina, captures notable share, with government-funded programs in São Paulo and Buenos Aires steering toward isotope self-sufficiency.